December 7, 2016
C. Jeantet
Le cannabis est la drogue illégale la plus consommée actuellement en France. Le Δ9-tétrahydrocannabinol (Δ9-THC), en tant qu’excocannabinoïde, a un impact sur le système visuel via le système endocannabinoïde. Physiologiquement, parmi les deux voies majoritairement responsables de la transmission de l’information visuelle aux stades les plus précoces, la voie magnocellulaire pourrait être la...
Schizophrenia Research: Cognition
December 1, 2016
Ashley M. Schnakenberg Martin, K. Bonfils, Beshaun J. Davis et al.
Literature on the relationship of cannabis use and cognition in schizophrenia provides the paradoxical view that cannabis use is sometimes linked with less severe impairment in neurocognition. This paper explored the possibility that this is a reflection of a dose related response between lifetime cannabis use and two forms of cognition, neurocognition and metacognition, in schizophrenia. It...
Journal of Medical Toxicology
December 2016
Milana Zaurova, Robert S Hoffman, David Vlahov et al.
Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at...
Psychological Medicine
December 2016
Michael Bloomfield, E Mouchlianitis, C J A Morgan et al.
Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. We tested 17 cannabis users and 17 age- and...
Arquivos de Neuro-Psiquiatria
December 1, 2016
Hélio A G Teive, Francisco M B Germiniani, Pedro A Kowacs et al.
Three world-famous neurologists, Charcot and Mitchell, in the 19th century, and Lees, in this century, all of whom had great scientific curiosity, experimented with the psychoactive drugs hashish, mescal and yagé, respectively, in an attempt to increase their knowledge of neurological diseases and how the brain works.
Translational Psychiatry
November 29, 2016
Claire Mokrysz, Tom P. Freeman, Saana M. Korkki et al.
111 citations
Preclinical research demonstrates that cannabinoids have differing effects in adolescent and adult animals. Whether these findings translate to humans has not yet been investigated. Here we believe we conducted the first study to compare the acute effects of cannabis in human adolescent (n=20; 16-17 years old) and adult (n=20; 24-28 years old) male cannabis users, in a placebo-controlled,...
November 15, 2016
Daniel G Barrus, Kristen Capogrossi, Sheryl Cates et al.
Food products containing cannabis extract (edibles) have emerged as a popular and lucrative facet of the legalized market for both recreational and medicinal cannabis. The many formulations of cannabis extracts used in edibles present a unique regulatory challenge for policy makers. Though edibles are often considered a safe, discreet, and effective means of attaining the therapeutic and/or...
Journal of Applied Toxicology
November 2016
Rebecca L Hartman, Timothy L Brown, Gary Milavetz et al.
Although evidence suggests cannabis impairs driving, its driving-performance effects are not fully characterized. We aimed to establish cannabis' effects on driving longitudinal control (with and without alcohol, drivers' most common drug combination) relative to psychoactive ∆(9) -tetrahydrocannabinol (THC) blood concentrations. Current occasional (≥1×/last 3 months, ≤3 days per week) cannabis...
Cell
October 20, 2016
Tian Hua, Kiran Vemuri, Mengchen Pu et al.
Cannabinoid receptor 1 (CB1) is the principal target of Δ9-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use. CB1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders. Here, we present the 2.8 Å...
Revista de medicina de la Universidad de Navarra
October 7, 2016
Luis Gutiérrez-Rojas
9 citations
Esta es la segunda parte de una revisión sobre los efectos adversos que presenta el consumo de cannabis sobre la salud de los jóvenes. La primera parte trató sobre los efectos adversos para la salud física y esta segunda parte trata de los efectos adversos sobre la salud psíquica. El cannabis ha sido considerado a veces como una droga relativamente menos peligrosa que otras, y además se le han...
The Lancet Psychiatry
October 1, 2016
Tabea Schoeler, Natalia Petros, Marta Di Forti et al.
BACKGROUND Although cannabis use after a first episode of psychosis has been associated with relapse, little is known about the determinants of this most preventable risk factor for relapse of psychosis. Here we aimed to study whether the effects on outcome vary depending on the type of cannabis consumed and usage pattern. METHODS In this observational study, we prospectively recruited and...
Psychopharmacology
October 2016
Zackary A Cope, Adam L. Halberstadt, Jordy Van Enkhuizen et al.
The five-choice serial reaction time task (5-CSRTT) is regularly used to study attention and impulsivity. In the 5-CSRTT, rodents initiate a trial, then after an inter-trial interval (ITI), a light appears in one of five holes. Responding in the lit vs. unlit hole reflects attention (accuracy), while responding prematurely before a light appears is suggested to reflect impulsivity/response...
JAMA Psychiatry
September 28, 2016
Tabea Schoeler, Natalia Petros, Marta Di Forti et al.
106 citations
IMPORTANCE: Cannabis use after first-episode psychosis is associated with poor outcomes, but the causal nature of this association is unclear. OBJECTIVE: To examine the precise nature of the association between continued cannabis use after the onset of psychosis and risk of relapse of psychosis. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study followed up for at least 2 years...
Substance Abuse Treatment, Prevention, and Policy
September 23, 2016
Ling‐yi Feng, Wenjing Yu, Wei-Ting Chang et al.
49 citations
While the problem of methamphetamine still lingers, NPS have emerged as a new issue in both countries. However, the NPS pattern was different between Taiwan and Korea. Although the controlled NPS items in Taiwan were far less than those in Korea, the quantity of total NPS seizures, especially with ketamine, was much larger in Taiwan than in Korea. Different NPS pattern may also imply they were...
World Psychiatry
September 22, 2016
Robin Murray, Harriet Quigley, Diego Quattrone et al.
319 citations
Epidemiological evidence demonstrates that cannabis use is associated with an increased risk of psychotic outcomes, and confirms a dose-response relationship between the level of use and the risk of later psychosis. High-potency cannabis and synthetic cannabinoids carry the greatest risk. Experimental administration of tetrahydrocannabinol, the active ingredient of cannabis, induces transient...
Psychopharmacology
September 2, 2016
Will Lawn, Tom P. Freeman, Rebecca Pope et al.
177 citations
RATIONALE: Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as well as associations with cannabis dependence. OBJECTIVES: The objectives of...
Pharmacological Research
September 2016
Erica Zamberletti, Marina Gabaglio, Massimo Grilli et al.
Cannabis use has been frequently associated with sex-dependent effects on brain and behavior. We previously demonstrated that adult female rats exposed to delta-9-tetrahydrocannabinol (THC) during adolescence develop long-term alterations in cognitive performances and emotional reactivity, whereas preliminary evidence suggests the presence of a different phenotype in male rats. To thoroughly...
Asian Journal of Pharmaceutical and Clinical Research
September 1, 2016
Sisira Padavala, Devaraj Ezhilarasan
10 citations
ABSTRACTCompounds in some plants have remarkable effects on the central nervous system. Plants containing those compounds are mind altering orpsychoactive in nature. These are consumed in the form of simple or complex preparations to affect the mind or alter the state of consciousness.Psychoactivity may include sedative, stimulant, euphoric, deliriant, and hallucinogenic effects. Several...
Drug and Alcohol Dependence
August 1, 2016
Lance R Mcmahon
Cannabidiol, a therapeutic with potential serotonin (5-hydroxytryptamine; 5-HT) 5-HT1A receptor agonist activity, is the second most prevalent cannabinoid in Cannabis after Δ(9)-THC. The extent to which cannabidiol modifies the effects of Δ(9)-THC has not been firmly established, especially with respect to abuse-related effects in rhesus monkeys where previously antagonistic interactions have...
American Journal of Psychiatry
August 1, 2016
Edison Manrique-Garcia, Antonio Ponce de Leon, Christina Dalman et al.
The authors assessed 1) the overall risk of death among cannabis users compared with nonusers and the extent to which psychosis affects excess mortality; 2) mortality among persons with psychotic disorders and the extent to which cannabis use affects excess mortality; and 3) the interaction effect of cannabis use and diagnosis of psychotic disorders on mortality. This was a longitudinal study...